HLSQ

SEC source: 0001213900-20-018301 · ownership.xml · nonDerivative · entry 1

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,217

F1 · kind: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

F1 · price: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

SEC source: 0001213900-20-018303 · ownership.xml · derivative · entry 4

PROPPER KERRY · CIK 0001282327 · 10% owner

Mountain Wood LLC · CIK 0001798364 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mountain Wood, LLC

Disclosed balance after: 0

Underlying: Common Stock · 2,900,000 shares

Expires 2024-10-28

F3 · kind: The shares were distributed by Mountain Wood LLC to its members.

F3 · price: The shares were distributed by Mountain Wood LLC to its members.

F2 · ownership.nature: The securities are held by Mountain Wood, LLC and may be deemed to be indirectly beneficially owned by Kerry Propper. Mr. Propper disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001213900-20-018303 · ownership.xml · derivative · entry 3

PROPPER KERRY · CIK 0001282327 · 10% owner

Mountain Wood LLC · CIK 0001798364 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 631,786

Underlying: Common Stock · 631,786 shares

Expires 2024-10-28

F1 · kind: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

F1 · price: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

SEC source: 0001213900-20-018303 · ownership.xml · nonDerivative · entry 2

PROPPER KERRY · CIK 0001282327 · 10% owner

Mountain Wood LLC · CIK 0001798364 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mountain Wood, LLC

Disclosed balance after: 0

F3 · kind: The shares were distributed by Mountain Wood LLC to its members.

F3 · price: The shares were distributed by Mountain Wood LLC to its members.

F2 · ownership.nature: The securities are held by Mountain Wood, LLC and may be deemed to be indirectly beneficially owned by Kerry Propper. Mr. Propper disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001213900-20-018303 · ownership.xml · nonDerivative · entry 1

PROPPER KERRY · CIK 0001282327 · 10% owner

Mountain Wood LLC · CIK 0001798364 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,771

F1 · kind: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

F1 · price: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

SEC source: 0001213900-20-018683 · ownership.xml · derivative · entry 2

Amusa Gbolahan · CIK 0001761120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,190

Underlying: Common Stock · 276,190 shares

Expires 2024-10-28

F1 · kind: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

F1 · price: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

SEC source: 0001213900-20-018683 · ownership.xml · nonDerivative · entry 1

Amusa Gbolahan · CIK 0001761120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,871

F1 · kind: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

F1 · price: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

SEC source: 0001213900-20-018301 · ownership.xml · nonDerivative · entry 2

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ravenna LLC

Disclosed balance after: 0

F2 · kind: The shares were distributed to the reporting person by Ravenna LLC, which distributed its securities in the issuer to its members.

F2 · price: The shares were distributed to the reporting person by Ravenna LLC, which distributed its securities in the issuer to its members.

F3 · ownership.nature: Consists of shares of common stock owned by Ravenna LLC, for which Mr. Grossman is the managing member. Mr. Grossman disclaims beneficial ownership of the shares except to the extent of his pecuniary interest in the shares.

SEC source: 0001213900-20-014895 · ownership.xml · nonDerivative · entry 1

Amusa Gbolahan · CIK 0001761120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,723

F1 · kind: The shares were distributed to the reporting person by Chardan Investments, LLC, which distributed its shares in the issuer to its members.

F1 · price: The shares were distributed to the reporting person by Chardan Investments, LLC, which distributed its shares in the issuer to its members.

SEC source: 0001213900-20-014897 · ownership.xml · nonDerivative · entry 3

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ravenna LLC

Disclosed balance after: 45,275

F1 · kind: The shares were distributed to the reporting person by Chardan Investments, LLC.

F1 · price: The shares were distributed to the reporting person by Chardan Investments, LLC.

F4 · ownership.nature: Consists of shares of common stock owned by Ravenna LLC, for which Mr. Grossman is the managing member. Mr. Grossman disclaims beneficial ownership of the shares except to the extent of his pecuniary interest in the shares.

SEC source: 0001213900-20-014897 · ownership.xml · nonDerivative · entry 2

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Chardan Investments, LLC

Disclosed balance after: 0

F2 · kind: Chardan Investments, LLC distributed the shares to its members.

F2 · price: Chardan Investments, LLC distributed the shares to its members.

F3 · ownership.nature: Consists of shares of common stock owned by Chardan Investments, LLC, for which Mr. Grossman is the managing member. Mr. Grossman disclaims beneficial ownership of the shares except to the extent of his pecuniary interest in the shares.

SEC source: 0001213900-20-014897 · ownership.xml · nonDerivative · entry 1

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,672

F1 · kind: The shares were distributed to the reporting person by Chardan Investments, LLC.

F1 · price: The shares were distributed to the reporting person by Chardan Investments, LLC.

SEC source: 0001213900-20-014899 · ownership.xml · nonDerivative · entry 2

PROPPER KERRY · CIK 0001282327 · 10% owner

Mountain Wood LLC · CIK 0001798364 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Mountain Wood, LLC

Disclosed balance after: 999,058

F1 · kind: The shares were distributed to the reporting person by Chardan Investments, LLC, which distributed all its shares to its members.

F1 · price: The shares were distributed to the reporting person by Chardan Investments, LLC, which distributed all its shares to its members.

F2 · ownership.nature: The securities are held by Mountain Wood, LLC and may be deemed to be indirectly beneficially owned by Kerry Propper. Mr. Propper disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001213900-20-014899 · ownership.xml · nonDerivative · entry 1

PROPPER KERRY · CIK 0001282327 · 10% owner

Mountain Wood LLC · CIK 0001798364 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,119

F1 · kind: The shares were distributed to the reporting person by Chardan Investments, LLC, which distributed all its shares to its members.

F1 · price: The shares were distributed to the reporting person by Chardan Investments, LLC, which distributed all its shares to its members.

SEC source: 0001213900-20-007664 · ownership.xml · derivative · entry 1

Greig Russell · CIK 0001789914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2030-03-25

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-20-007672 · ownership.xml · derivative · entry 1

Amusa Gbolahan · CIK 0001761120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2030-03-25

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-20-007671 · ownership.xml · derivative · entry 2

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2030-03-25

F3 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-20-007668 · ownership.xml · derivative · entry 3

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2030-03-25

F2 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-20-007660 · ownership.xml · derivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2030-03-25

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-20-007673 · ownership.xml · derivative · entry 1

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,500

Underlying: Common Stock · 31,500 shares

Expires 2030-03-25

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

F2 · balance_after: Does not include 284,996 additional options previously granted to the Reporting Person which have different exercise prices and which vest on different schedules.

SEC source: 0001213900-20-007667 · ownership.xml · derivative · entry 1

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,000

Underlying: Common Stock · 144,000 shares

Expires 2030-03-25

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

F2 · balance_after: Does not include 835,986 additional options previously granted to the Reporting Person which have different exercise prices and which vest on different schedules.

SEC source: 0001213900-20-007661 · ownership.xml · derivative · entry 1

Breski Yaron · CIK 0001792673 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2030-03-25

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-20-007663 · ownership.xml · derivative · entry 1

Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 67,500

Underlying: Common Stock · 67,500 shares

Expires 2030-03-25

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

F2 · balance_after: Does not include 263,576 additional options previously granted to the Reporting Person which have different exercise prices and which vest on different schedules.

F3 · ownership.nature: The options are held by SPB Consulting LLC. The Reporting Person is the sole member of SPB Consulting LLC and may be deemed the indirect beneficial owner of the securities held by SPB Consulting LLC.

SEC source: 0001213900-20-007662 · ownership.xml · derivative · entry 1

Wolfson Marina · CIK 0001797360 · Principal Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2030-03-25

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-19-027219 · ownership.xml · derivative · entry 2

GROSSMAN JONAS · CIK 0001423905 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,900,000 shares

Expires 2024-10-28

F1 · kind: Represents private warrants held by Mountain Wood, LLC of which Jonas Grossman ceased to be managing member on December 20, 2019. Upon Mr. Grossman no longer being managing member of Moutain Wood, LLC, he ceased to beneficially own the shares held by Mountain Wood, LLC.

F1 · ownership.nature: Represents private warrants held by Mountain Wood, LLC of which Jonas Grossman ceased to be managing member on December 20, 2019. Upon Mr. Grossman no longer being managing member of Moutain Wood, LLC, he ceased to beneficially own the shares held by Mountain Wood, LLC.

SEC source: 0000947871-19-000982 · ownership.xml · nonDerivative · entry 2

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,313,489

F1 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities.

F2 · ownership.nature: Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000983 · ownership.xml · nonDerivative · entry 2

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,313,489

F1 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.

F2 · ownership.nature: By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000982 · ownership.xml · nonDerivative · entry 1

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,309,989

F1 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities.

F2 · ownership.nature: Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000983 · ownership.xml · nonDerivative · entry 1

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,309,989

F1 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.

F2 · ownership.nature: By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000962 · ownership.xml · nonDerivative · entry 2

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,309,489

F1 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,668,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities.

F2 · ownership.nature: Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000961 · ownership.xml · nonDerivative · entry 2

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,309,489

F1 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,668,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.

F2 · ownership.nature: By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000962 · ownership.xml · nonDerivative · entry 1

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,304,089

F1 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,668,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities.

F2 · ownership.nature: Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000961 · ownership.xml · nonDerivative · entry 1

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,304,089

F1 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,668,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.

F2 · ownership.nature: By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000947 · ownership.xml · nonDerivative · entry 3

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,300,689

F1 · balance_after: Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Person's Form 3.

F2 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000948 · ownership.xml · nonDerivative · entry 3

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,300,689

F1 · balance_after: Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Persons' Form 3.

F2 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.

F3 · ownership.nature: By virtue of the relationships described in footnote 2, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000947 · ownership.xml · nonDerivative · entry 2

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,294,689

F1 · balance_after: Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Person's Form 3.

F2 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000948 · ownership.xml · nonDerivative · entry 2

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,294,689

F1 · balance_after: Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Persons' Form 3.

F2 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.

F3 · ownership.nature: By virtue of the relationships described in footnote 2, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000947 · ownership.xml · nonDerivative · entry 1

Chimovits Erez · CIK 0001706399 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,293,889

F1 · balance_after: Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Person's Form 3.

F2 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-19-000948 · ownership.xml · nonDerivative · entry 1

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,293,889

F1 · balance_after: Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Persons' Form 3.

F2 · ownership.nature: The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.

F3 · ownership.nature: By virtue of the relationships described in footnote 2, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001213900-19-024217 · ownership.xml · nonDerivative · entry 3

GROSSMAN JONAS · CIK 0001423905 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.89 to $8.30, inclusive.

SEC source: 0001213900-19-024217 · ownership.xml · nonDerivative · entry 2

GROSSMAN JONAS · CIK 0001423905 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,100

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.25 to $7.95, inclusive.

SEC source: 0001213900-19-024217 · ownership.xml · derivative · entry 5

GROSSMAN JONAS · CIK 0001423905 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,129

Underlying: Common Stock · 25,064 shares

Expires 2024-10-28

F5 · price: The price reported in Column 4 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.50 to $0.65, inclusive.

SEC source: 0001213900-19-024217 · ownership.xml · nonDerivative · entry 1

GROSSMAN JONAS · CIK 0001423905 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.925 to $7.00, inclusive. The reporting person undertakes to provide to the issuer, and security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in footnotes (1), (2) and (4) of this Form 4.

SEC source: 0001615774-18-014650 · ownership.xml · derivative · entry 1

GROSSMAN JONAS · CIK 0001423905 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,900,000

Underlying: Common Stock · 2,900,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The warrants become exercisable on the later of (i) 30 days from the completion of the registrant's initial business combination and (ii) 12 months from the closing of the registrant's initial public offering.

F2 · derivative.expiration_date: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC.

F3 · ownership.nature: Represents private warrants held by Mountain Wood, of which Jonas Grossman has voting and dispositive power over.